Company intelligence / Profile preview
Taiwan Liposome Company
Taipei, Taipei City, Taiwantlcbio.com ↗
- Ownership
- Private
- Employees
- ~105
- Development stage
- Phase 2
01
Overview
Lead product TLC599 (dexamethasone sodium phosphate SR) is in Phase III clinical trial for osteoarthritis knee pain. Other products include TLC590 (completed Phase II for post-surgical pain), TLC399 (Phase II for ophthalmology), TLC178 (Phase I/II for rhabdomyosarcoma), and TLC19 (Phase I for COVID-19).
- Therapeutic areas
- RheumatologyOphthalmologyOncologyNeurologyInfectious Diseases
- Modalities
- Lipid-based drug delivery systemsNanomedicinesLiposomal formulationsRNA therapeutics
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Taiwan Liposome Company.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Taiwan Liposome Company.